AlphAIAlphAI — Financial news for AI agents
globenewswire.comOCT 22 min read$SCNX

SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals

Scienture Holdings (SCNX) announced that its Arbli™ (losartan potassium) Oral Suspension has been added to the formularies of three leading U.S. pediatric medical centers. Arbli™ addresses a $219 million U.S. losartan market, with 72 million prescriptions annually. The company reported increasing wholesale orders and sees significant growth potential, especially in pediatric care.

Original reporting
globenewswire.com
Published Oct 2, 2026, 12:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 12:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$SCNX
Bullish
high confidence
Mentioned
$SCNX
Relevance
6/10
AlphAI data visualization · based on globenewswire.com
Decision brief

The 30-second read

$SCNXBullishMed
01

Why it matters

The formulary additions provide a new distribution channel and may accelerate revenue growth, but actual sales impact depends on hospital purchasing cycles and payer coverage.

02

Market read

First disclosure of a significant institutional win for SCNX, potentially boosting its stock on the news.

03

What to watch

Reimbursement negotiations and competition from generic losartan could limit upside.

Relevance 6/10Novelty 7/10Timing: today

Background

Scienture Holdings (NASDAQ: SCNX) focuses on specialty pharmaceuticals. Arbli™ is a liquid losartan formulation targeting pediatric and other patients who cannot swallow tablets.

Company-level read

Ticker impact

$SCNXBullishHigh confidence
Context

SCNX announced that its Arbli™ oral suspension was added to the formularies of three leading U.S. pediatric academic medical centers, marking a new institutional adoption milestone.

Expected impact

likely upward pressure as market penetration and wholesale orders grow.

Evidence & confidence

First report of a formulary win for a niche pediatric drug; expands addressable market and could boost revenue forecasts.

Market effects

Sector

May signal broader acceptance of pediatric liquid formulations, benefiting specialty pharma peers.

Regional

U.S. pediatric hospital market sees new product adoption.

Global

Limited to U.S. institutional rollout; modest global effect.

Counterpoint

What could challenge this read

Adoption could be slower than projected; formulary inclusion does not guarantee volume growth.

Key entities

  • Company
    Scienture Holdings, Inc.

    Parent company of the Arbli™ product line.

  • Product
    Arbli™

    Oral suspension of losartan potassium for pediatric hypertension.

Read at source← All news

Related articles

AUG 20
$SCNXMed

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

Scienture Holdings, Inc. (SCNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company’s Growing Commercial Revenue Base Q2 2026 Operat

SEC EDGAR 8-K2 min
AUG 14
$SCNXMedAI 8/10

Scienture Holdings, Inc.: SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

Scienture Holdings (NASDAQ: SCNX) reported Q2 2026 results: revenue rose about 510% sequentially to $343,639 from $56,325 in Q1. Q2 gross margin was about 97.7%. Operating loss improved about 48% to ~$2.7M and net loss narrowed about 58% to ~$2.8M. The company began commercial launch of REZENOPY and cited USPTO patent grants and expanded payer coverage.

finanznachrichten.de4 min
AUG 14
$SCNXMedAI 8/10

SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product

Scienture (NASDAQ:SCNX) says it has commercially launched REZENOPY, a 10 mg naloxone hydrochloride nasal spray, after fulfilling initial U.S. wholesaler purchase orders and starting nationwide distribution. The company cites IQVIA data for a $143 million U.S. naloxone market (9.8 million units) and says payer coverage could exceed 100 million lives via GPO access to 5,000+ facilities. No revenue guidance was provided.

yahoo.com5 min
JUL 10
$SCNXMed

Scienture Announces Commercial Inventory Readiness For REZENOPY Naloxone Nasal Spray; Stock Up

Scienture Holdings (SCNX) said it completed manufacturing commercial launch inventory for REZENOPY naloxone nasal spray 10 mg and will start shipments to U.S. wholesalers in July, with broad availability expected in August. The company cited IQVIA data valuing the U.S. naloxone market at about $144 million annually and said payer access could cover over 100 million lives.

rttnews.com3 min
JUN 2
$SCNXMedAI 9/10

SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041

Scienture Holdings (NASDAQ: SCNX) said the U.S. Patent and Trademark Office granted U.S. Patent No. 12,622,903 B2 covering REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, effective May 12, 2026 and expiring Feb. 5, 2041. The patent was issued to Summit Biosciences, a subsidiary of Kindeva. Scienture’s subsidiary has exclusive U.S. commercialization rights; REZENOPY™ was FDA-approved April 19, 2024. IQVIA data cited: ~$141M annual U.S. naloxone sales and 9.4M units (MAT Jan 2026).

manilatimes.net4 min